JD MBA - Virpax Pharmaceuticals Chief Officer
| VRPXDelisted Stock | USD 0.25 0.04 19.05% |
Insider
JD MBA is Chief Officer of Virpax Pharmaceuticals
| Phone | 610 727 4597 |
| Web | https://www.virpaxpharma.com |
Virpax Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.3501) % which means that it has lost $1.3501 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (23.6482) %, meaning that it created substantial loss on money invested by shareholders. Virpax Pharmaceuticals' management efficiency ratios could be used to measure how well Virpax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Virpax Pharmaceuticals currently holds 2.47 B in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Virpax Pharmaceuticals has a current ratio of 11.6, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Virpax Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Virpax Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Virpax Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Virpax to invest in growth at high rates of return. When we think about Virpax Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| James Ahlers | RenovoRx | 60 | |
| Michael Newman | Indaptus Therapeutics | 69 | |
| Angela Nelms | RenovoRx | 47 | |
| Eric JD | Lixte Biotechnology Holdings | 46 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 63 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
| Jeffrey Meckler | Indaptus Therapeutics | 57 | |
| MPH MD | NRX Pharmaceuticals | 68 | |
| Michael Kunz | NRX Pharmaceuticals | 59 | |
| Ronald CPA | RenovoRx | N/A | |
| Ramtin MD | RenovoRx | 59 | |
| Robert Weingarten | Lixte Biotechnology Holdings | 73 | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 41 | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
| Walt Esq | Indaptus Therapeutics | 64 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 47 | |
| Molly Cogan | NRX Pharmaceuticals | N/A | |
| James MD | Lixte Biotechnology Holdings | 77 | |
| John MD | Lixte Biotechnology Holdings | 87 | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
Management Performance
| Return On Equity | -23.65 | ||||
| Return On Asset | -1.35 |
Virpax Pharmaceuticals Leadership Team
Elected by the shareholders, the Virpax Pharmaceuticals' board of directors comprises two types of representatives: Virpax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virpax. The board's role is to monitor Virpax Pharmaceuticals' management team and ensure that shareholders' interests are well served. Virpax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virpax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Sec | ||
| Jeffrey MD, Chief VP | ||
| JD MBA, Chief Officer | ||
| Usama Chaudhry, Chief Officer | ||
| MBA ACA, Principal CFO | ||
| Shana Panzarella, Chief Staff | ||
| Anthony MBA, Chairman CEO | ||
| Jatinder Dhaliwal, CEO Director | ||
| Gerald Bruce, CEO Director |
Virpax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Virpax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -23.65 | ||||
| Return On Asset | -1.35 | ||||
| Current Valuation | (1.21 M) | ||||
| Shares Outstanding | 1.24 M | ||||
| Shares Owned By Insiders | 0.96 % | ||||
| Shares Owned By Institutions | 0.41 % | ||||
| Number Of Shares Shorted | 577.07 K | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | (12.08 B) | ||||
| Net Income | (12.07 B) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Virpax Pink Sheet
If you are still planning to invest in Virpax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virpax Pharmaceuticals' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |